1369801-93-3

Upstream product

• 1369801-99-9 prop-2-en-1-yl-2-{[(4'-chlorobiphenyl-4-yl)methyl]sulfanyl}-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoate 
• 1369801-97-7 2-(4'-chlorobiphenyl-4-ylmethylsulfanyl)-4-hydroxybutyric acid allyl ester 
• 1369801-95-5 (2-{[(4'-chlorobiphenyl-4-yl)methyl]sulfanyl}-4-hydroxybutanoyl)sodium 
• 1369801-94-4 3-{[(4'-chlorobiphenyl-4-yl)methyl]sulfanyl}dihydrofuran-2(3H)-one 
• 1369800-37-2 3-[(4-bromobenzyl)sulfanyl]dihydrofuran-2(3H)-one 
• 589-15-1 1-bromomethyl-4-bromobenzene 

Relevant academic research and scientific papers

MATRIX METALLOPROTEINASE INHIBITORS

This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, periodontitis, multiple sclerosis, gingivitis, gingivitis, atherosclerosis, dry eye, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and pounds.

MATRIX METALLOPROTEINASE INHIBITORS

This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation, which leads to restenosis and ischemic heart faliure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over-activation of matrix metalloproteinase using the compounds.